Friday, March 25, 2011
Stemedica Cell Technologies Inc., of San Diego, said its ischemic adult allogeneic mesenchymal stem cells were used successfully to treat the first patient in an ischemic stroke study. A total of 35 patients will be enrolled in the study, which is designed to determine tolerance and therapeutic outcomes for the intravenously delivered stem cells.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.